Certain studies reported a significant overexpression of LEF1-AS1 in osteosarcoma, prostate cancer, and retinoblastoma (Liu et al., 2019; Li W. et al., 2020; He and Qin, 2020; Lu et al., 2020). Here, LEF1 is linked to prostate cancer.